Fulgent Genetics Inc (FLGT) Forms Bearish Double Bottom Chart Pattern; Strong Momentum for Sellers

September 17, 2017 - By Hazel Jackson

The chart of Fulgent Genetics Inc (FLGT) shows a double bottom with $4.72 target or 5.00 % below today’s $4.97 share price. The 7 months chart pattern indicates high risk for the $88.17 million company. It was reported on Sep, 17 by Finviz.com. If the $4.72 price target is reached, the company will be worth $4.41M less. Double bottoms are rare but powerful chart patterns.

The stock decreased 4.79% or $0.25 on September 15, reaching $4.97. About 97,225 shares traded or 161.16% up from the average. Fulgent Genetics Inc (NASDAQ:FLGT) has 0.00% since September 17, 2016 and is . It has underperformed by 16.70% the S&P500.

Fulgent Genetics Inc (NASDAQ:FLGT) Ratings Coverage

Among 2 analysts covering Fulgent Genetics (NASDAQ:FLGT), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Fulgent Genetics had 2 analyst reports since October 24, 2016 according to SRatingsIntel. Credit Suisse initiated Fulgent Genetics Inc (NASDAQ:FLGT) on Monday, October 24 with “Outperform” rating. The rating was initiated by Piper Jaffray on Monday, October 24 with “Overweight”.

More notable recent Fulgent Genetics Inc (NASDAQ:FLGT) news were published by: Seekingalpha.com which released: “IPO Preview: Fulgent Genetics, Inc.” on September 27, 2016, also Quotes.Wsj.com with their article: “Fulgent Genetics Inc.” published on September 24, 2016, Gurufocus.com published: “Fulgent Genetics Inc (FLGT) President and CEO Ming Hsieh Bought $105200 of Shares” on June 16, 2017. More interesting news about Fulgent Genetics Inc (NASDAQ:FLGT) were released by: Seekingalpha.com and their article: “Fulgent Genetics’s (FLGT) CEO Ming Hsieh on Q2 2017 Results – Earnings Call …” published on August 07, 2017 as well as Globenewswire.com‘s news article titled: “Fulgent Genetics, Inc. Announces Pricing of Initial Public Offering” with publication date: September 28, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.